Market Report, "Hungary Pharmaceuticals & Healthcare Report Q1 2013", Published
BMI View: Our outlook for Hungary's pharmaceutical market remains negative, given the government's policies that shift the burden of the National Healthcare Fund (OEP) on to drug manufacturers. Pricing pressure and claw-back taxes have squeezed domestic manufacturers' margins and introduced insecurity to an already difficult economic environment, and we continue to expect a contraction in the size of the Hungarian pharmaceutical market in 2012 and 2013. Consequently, Hungarian drugmakers will have to become even more export-orientated. That said, a favourable...
View full press release